LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

Inicio・Lista de Acciones・BioNTech SE ADR

BioNTech SE ADR

Cerrado

SectorSalud

97.13 4.72

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

92.75

Máximo

97.35

Métricas clave
By Trading Economics
Ingresos	143M 301M
Ventas	-55M 1.2B
BPA	-1.821
Margen de beneficio	25.311
Empleados	6,772
EBITDA	253M 464M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+51.45% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-852M 25B
Apertura anterior	92.41
Cierre anterior	97.13

Noticias sobre sentimiento de mercado

By Acuity

45%

55%

173 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

92.4 / 103.5 Soporte y Resistencia

BioNTech SE ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 feb 2025, 18:52 UTC

Principales Movimientos del Mercado

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 nov 2024, 10:28 UTC

Principales Movimientos del Mercado

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

5 may 2025, 15:13 UTC

Charlas de Mercado

Ganancias

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

15 nov 2024, 11:14 UTC

Charlas de Mercado

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 nov 2024, 10:34 UTC

Charlas de Mercado

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 ago 2024, 10:02 UTC

Ganancias

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 ago 2024, 10:01 UTC

Ganancias

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 ago 2024, 10:01 UTC

Ganancias

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 ago 2024, 10:00 UTC

Ganancias

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Loss EUR807.8M >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Rev EUR128.7M >BNTX

Comparación entre iguales

Cambio de precio

BioNTech SE ADR Esperado

Precio Objetivo

By TipRanks

51.45% repunte

Estimación a 12 meses

Media 140.5 USD 51.45%

Máximo 171 USD

Mínimo 110 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioNTech SE ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para BioNTech SE ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

92.4 / 103.5Soporte y Resistencia

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

173 / 382 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac